NCT03317366No Longer Available不适用
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)0 个研究点开始时间: 2017年10月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent access to ARQ 092 through an existing clinical trial.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe overgrowth diseases and/or vascular anomalies with confirmed somatic genetic alterations of PIK3CA or AKT
- •Are unable to participate in an ongoing ARQ 092 clinical trial
- •Willing and able to provide written, signed informed consent. In the case of a minor, a parent or legal guardian must sign an informed consent form.
- •Medically suitable for treatment with ARQ 092
- •Not eligible for any other available therapy for the diagnosed overgrowth disease and/or vascular anomaly with confirmed somatic genetic alterations of PIK3CA or AKT
排除标准
- •Currently enrolled in an ongoing clinical study of ARQ 092 or other investigational drug
- •Currently being treated with any inhibitor of the PI3K/AKT/mTOR pathway
研究者
相似试验
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAcute Lymphoblastic LeukemiaMantle Cell LymphomaNCT05776134Kite, A Gilead Company
Available
不适用
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCANCT06034886Biohaven Pharmaceuticals, Inc.
No Longer Available
不适用
AZD9291 US Expanded Access ProgramEGFR T790M Mutation Positive NSCLCNCT02451852AstraZeneca
Available
不适用
IFx-Hu2.0 Expanded Access ProgramCutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVCutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaNCT04853602TuHURA Biosciences, Inc.